Inaktiver Wert

Anacor Pharmaceuticals Inc Aktie

Aktien

Schlusskurs Nasdaq Andere Börsenplätze
- ^USD	-

Anacor Pharmaceuticals : received rival bid before Pfizer deal - filing	26.05.16
Ryan & Maniskas, LLP : Announces Investigation of Anacor Pharmaceuticals, Inc.	18.05.16
Brower Piven Commences an Investigation into the Proposed Sale of Anacor Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm for Additional Information	17.05.16
Brower Piven Commences an Investigation into the Proposed Sale of Anacor Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm for Additional Information	16.05.16
Anacor Pharmaceuticals : Pfizer to buy Anacor in $5.2 billion deal for access to eczema gel	16.05.16

Manager	Titel	Alter	Seit
Douglas Giordano CEO	Chief Executive Officer	61	24.06.16
Jacob John Plattner CTO	Chief Tech/Sci/R&D Officer	77	01.02.04
Margaret M. Madden BRD	Director/Board Member	-	24.06.16

Aufsichtsräte	Titel	Alter	Seit
Douglas Giordano CEO	Chief Executive Officer	61	24.06.16
Bryan Supran BRD	Director/Board Member	-	24.06.16
Margaret M. Madden BRD	Director/Board Member	-	24.06.16

Sektor

	% 1. Jan.	Kap.
IQVIA HOLDINGS INC.	+1,51 %	42,75 Mrd.
LONZA GROUP AG	+49,22 %	41,61 Mrd.
MODERNA, INC.	+8,57 %	41,34 Mrd.
CELLTRION, INC.	-12,36 %	26,59 Mrd.
ICON PUBLIC LIMITED COMPANY	+8,92 %	25,49 Mrd.
ALNYLAM PHARMACEUTICALS, INC.	-25,13 %	18,12 Mrd.
MEDPACE HOLDINGS, INC.	+29,17 %	12,24 Mrd.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3,12 %	11,76 Mrd.
UNITED THERAPEUTICS CORPORATION	+6,35 %	11 Mrd.